【レポートの概要（一部）】
1. Report Overview
1.1 Global Pain Relieving Drugs: Market Overview
1.2 Global Pain Relieving Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction to Pain and Pain Management
2.1 Pain: A Sensory And Emotional Phenomenon
2.1.1 Pain: A Short History
2.1.2 Pain Pathways And The Origin Of Pain
2.2 The World Health Organisation (WHO) Pain Ladder
2.2.1 Classification Of Pain
2.2.1.1 Acute Pain
2.2.1.2 Chronic Pain
2.3 The Psychosocial Effects Of Chronic Pain
2.3.1 Chronic Cancer Pain
2.3.2 Neuropathic Pain
2.3.3 Identifying Neuropathic Pain
2.4 The Neurochemistry Of Pain
2.4.1 Prostaglandins
2.4.2 Opioids
2.5 Pain Management – A Brief Overview
2.6 Pain Management Drugs
2.6.1 The Use Of Opioids In Pain Treatment
2.6.2 OTC Pain Relievers
2.7 Market Definition
3. World Pain Relieving Drugs Market 2014-2024
3.1 Global Pain Relieving Drugs: Market Overview
3.1.1 Categorisation of the Global Pain Relieving Drug Market
3.1.2 Pain Relieving Drugs: A Growing Market
3.2 The Global Pain Relieving Drugs Market in 2013
3.2.1 Market Dominance of Arthritic Pain Relieving Drugs
3.3 Global Pain Relieving Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Abuse Deterrents and Safety Measures Will Boost Narcotic Pain Relieving Drugs Market Growth
3.3.3 Changing Market Shares by Sector 2014-2024
4. Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
4.1 The Global Narcotic Pain Relieving Drugs Market in 2013
4.1.1 Global Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
4.1.2 Changing Market Shares By Leading Drugs 2014-2024
4.2 Opana ER (Endo Pharmaceuticals): Market Analysis
4.2.1 Tamper-Proof Opana ER Products
4.2.2 Opana ER: Historical Sales Analysis, 2014-2024
4.2.3 Opana ER: Sales Forecast 2014-2024
4.3 Duragesic: Market Analysis
4.3.1 Duragesic: Historical Sales Analysis, 2011-2013
4.3.2 Duragesic: Sales Forecast 2014-2024
4.4 Oxycontin ER: Market Analysis
4.4.1 Tamper Resistant Oxycontin ER
4.4.2 Oxycontin ER: Patent Expiries and Legal Battles
4.4.3 Oxycontin ER: Sales Forecast 2014-2024
4.5 Ultram: Market Analysis
4.5.1 Ultram: Sales Forecast 2014-2024
4.6 Zaldiar/Ixprim: Market Analysis
4.6.1 Zaldiar/Ixprim: Historical Sales Analysis, 2011-2013
4.6.2 Zaldiar/Ixprim: Sales Forecast 2014-2024
4.7 Other Narcotic Pain Relieving Drugs
4.7.1 Subsys (Insys Therapeutics)
4.7.2 Oxecta (Pfizer)
4.7.3 Other Narcotic Pain Relieving Drugs: Sales Forecast 2014-2024
5. Non-Narcotic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
5.1 The Global Non-Narcotic Pain Relieving Drugs Market in 2013
5.1.1 Global Non-Narcotic Pain Relieving Drugs: Market Forecast 2014-2024
5.1.2 Changing Market Shares By Leading Drugs 2014-2024
5.2 Aspirin (Bayer): Market Analysis
5.2.1 Aspirin (Bayer): Historical Sales Analysis, 2010-2013
5.2.2 Aspirin (Bayer): Sales Forecast 2014-2024
5.3 Panadol: Market Analysis
5.3.1 Panadol: Historical Sales Analysis, 2008-2013
5.3.2 Panadol: Sales Forecast 2014-2024
5.4 Advil: Market Analysis
5.4.1 Advil: Historical Sales Analysis, 2012 and 2013
5.4.2 Advil: Sales Forecast 2014-2024
5.5 Tylenol: Market Analysis
5.5.1 Tylenol: Sales Forecast 2014-2024
5.6 Other Non-Narcotic Pain Drugs
5.6.1 Exparel (Pacira Pharmaceuticals)
5.6.2 Other Non-Narcotic Pain Drugs: Sales Forecast 2014-2024
6. Neuropathic Pain Relieving Drugs: World Market Analysis and Forecast 2014-2024
6.1 An Introduction to Neuropathic Pain
6.1.1 Identifying Neuropathic Pain
6.1.2 Pharmacological Interventions for Neuropathic Pain
6.1.2.1 Analgesics in Neuropathic Pain
6.1.2.2 Anti-Convulsants
6.1.2.3 Local Anaesthetics
6.1.2.4 Anti-Depressants
6.1.2.5 Aldose Reductase Inhibitors
6.1.3 The Global Neuropathic Pain Relieving Drugs Market in 2013
6.1.4 Global Neuropathic Pain Relieving Drugs: Market Forecast 2014-2024
6.1.5 Changing Market Shares By Leading Drugs 2014-2024
6.2 Lidoderm: Market Analysis
6.2.1 Lidoderm Patent Expiry and Endo Pharma – Watson/Actavis Agreement
6.2.2 Lidoderm Marketing Probe
6.2.3 Lidoderm: Historical Sales Analysis, 2009-2013
6.2.4 Lidoderm: Sales Forecast 2014-2024
6.3 Lyrica: Market Analysis
6.3.1 Lyrica: Historical Sales Analysis, 2009-2013
6.3.2 Lyrica: Sales Forecast 2014-2024
6.4 Cymbalta: Market Analysis
6.4.1 Cymbalta: Historical Sales Analysis, 2008-2013
6.4.2 Cymbalta: Sales Forecast 2014-2024
6.5 Neurontin: Market Analysis
6.5.1 Neurontin: Historical Sales Analysis, 2009-2013
6.5.2 Neurontin: Sales Forecast 2014-2024
6.6 Nucynta: Market Analysis
6.6.1 Nucynta: Historical Sales Analysis, 2011-2013
6.6.2 Nucynta: Sales Forecast 2014-2024
6.7 Other Neuropathic Pain Relieving Drugs
6.7.1 Retigabine (GSK; Valeant)
6.7.2 Other Neuropathic Pain Relieving Drugs: Sales Forecast 2014-2024
7. Anti-Migraine Drugs: World Market Analysis and Forecast 2014-2024
7.1 Migraine: An Introduction
7.1.1 Management of Migraine
7.1.2 Drugs Being Used In the Treatment of Migraine
7.1.3 Other Migraine Relieving Techniques
7.1.4 The Global Anti-Migraine Pain Relieving Drugs Market in 2013
7.1.5 Global Anti-Migraine Pain Relieving Drugs: Market Forecast 2014-2024
7.1.6 Changing Market Shares By Leading Drugs 2014-2024
7.2 Relpax: Market Analysis
7.2.1 Relpax: Historical Sales Analysis, 2009-2013
7.2.2 Relpax: Sales Forecast 2014-2024
7.3 Maxalt: Market Analysis
7.3.1 Maxalt: Historical Sales Analysis, 2008-2013
7.3.2 Maxalt: Sales Forecast 2014-2024
7.4 Imitrex/Imigran: Market Analysis
7.4.1 Imitrex/Imigran: Historical Sales Analysis, 2008-2013
7.4.2 Imitrex/Imigran: Sales Forecast 2014-2024
7.5 Zomig: Market Analysis
7.5.1 Zomig: Licensing Transfers and Exclusivity
7.5.2 Zomig: Historical Sales Analysis, 2009-2013
7.5.3 Zomig: Sales Forecast 2014-2024
7.6 Botox (Allergan): Market Analysis
7.6.1 Botox: Historical Sales Analysis, 2009-2013
7.6.2 Botox: Sales Forecast 2014-2024
7.7 Treximet: Market Analysis
7.7.1 Treximet: Agreements Between GSK, Pozen Pharmaceuticals and Pernix Therapeutics
7.7.2 The Generic Treats to Treximet
7.7.3 Treximet: Historical Sales Analysis, 2008-2013
7.7.4 Treximet: Sales Forecast 2014-2024
7.8 Axert: Market Analysis
7.8.1 Axert: Historical Sales Analysis, 2011-2013
7.8.2 Axert: Sales Forecast 2014-2024
7.9 Other Anti-Migraine Pain Relieving Drugs: Sales Forecast, 2014-2024
7.10 Anti-Migraine Pain Relieving Drugs Market – Future Prospects
7.10.1 Unmet Needs in the Treatment of Migraine
8. Anti-Arthritic Pain Drugs: World Market Analysis and Forecast 2014-2024
8.1 Understanding Arthritis: An Introduction to its Aetiology and Prevalence
8.1.1 Management of Arthritic Conditions
8.1.2 Drugs Being Used In The Treatment Of Arthritis
8.1.2.1 Analgesics As Pain Relieving Drugs
8.1.2.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
8.1.2.3 Corticosteroids
8.1.2.4 Disease Modifying Anti-Rheumatic Drugs (DMARDS)
8.1.3 Biological Drugs in the Treatment Of Arthritis
8.1.3.1 Biologics Used for Rheumatoid Arthritis
8.1.3.2 The Potential Side Effects of Biologics in the Treatment of Arthritis
8.1.4 The Global Anti-Arthritis Pain Relieving Drugs Market in 2013
8.1.5 Global Anti-Arthritis Pain Relieving Drugs: Market Forecast 2014-2024
8.1.6 Changing Market Shares By Leading Drugs, 2014-2024
8.2 Humira: Market Analysis
8.2.1 Humira: Historical Sales Analysis, 2011-2013
8.2.2 Humira: Sales Forecast 2014-2024
8.3 Enbrel: Market Analysis
8.3.1 Enbrel: Co-Promotions and Marketing Rights
8.3.2 Enbrel: Historical Sales Analysis, 2008-2013
8.3.3 Enbrel: Patent Expiries and Potential Competition, 2014-2024
8.3.4 Enbrel: Sales Forecast 2014-2024
8.4 Remicade: Market Analysis
8.4.1 Remicade: Historical Sales Analysis, 2008-2013
8.4.2 Remicade: Patent Expiries and Potential Competition, 2014-2024
8.4.3 Remicade: Sales Forecast 2014-2024
8.5 Voltaren: Market Analysis
8.5.1 Voltaren: Historical Sales Analysis, 2008-2013
8.5.2 Voltaren: Sales Forecast 2014-2024
8.6 Rituxan (Rituximab, MabThera): Market Analysis
8.6.1 Rituxan: Historical Sales Analysis, 2008-2013
8.6.2 Rituxan: Patent Expiries and Potential Competition, 2014-2024
8.6.3 Rituxan: Sales Forecast 2014-2024
8.7 Celebrex: Market Analysis
8.7.1 Celebrex: Historical Sales Analysis, 2008-2013
8.7.2 Celebrex: Patents, Exclusivity, and Competition, 2014-2024
8.7.3 Celebrex: Sales Forecast 2014-2024
8.8 Arcoxia: Market Analysis
8.8.1 Arcoxia: Historical Sales Analysis, 2008-2013
8.8.2 Arcoxia: Sales Forecast 2014-2024
8.9 Other Anti-Arthritis Pain Relieving Drugs
8.9.1 Duexa (Horizon Pharma)
8.9.2 Lodotra/RAYOS (Horizon Pharma; SkyePharma)
8.9.3 Ofatumumab (Genmab, GSK)
8.9.4 Other Anti-Arthritis Pain Relieving Drugs: Sales Forecast 2014-2024
8.10 Anti-Arthritic Pain Relieving Drug Market – Future Prospects
9. Leading National Markets for Pain Relieving Drugs 2014-2024
9.1 The Pain Relieving Drug Market By Region
9.1.1 The Global Distribution of Pain Relieving Drugs In 2013
9.2 Leading National Markets: Forecast, 2014-2024
9.2.1 Changing Market Shares By Region, 2014-2024
9.3 Regional Pain Relieving Drugs Markets: Analysis and Forecasts, 2014-2024
9.4 United States: The Largest Pain Relieving Drug Market
9.5 The EU5 Markets
9.5.1 EU5 Markets: Changing Market Shares by Country, 2014-2024
9.5.2 Germany
9.5.3 UK
9.5.4 France
9.5.5 Italy
9.5.6 Spain
9.6 Japan
9.7 China
9.8 South Korea
9.9 Brazil
9.10 India
9.11 Russia
9.12 Turkey
9.13 Rest of the World
10. Pain Relieving Drugs: R&D Pipeline 2014-2024
10.1 Innovative Products Currently In Development Will Drive Growth
10.1.1 Large Developmental Pipelines Encouraged By High Potential Growth
10.2 Development Pipeline For Narcotic Pain Relieving Drugs, 2014
10.2.1 Remoxy (Durect, Pain Therapeutics, Pfizer)
10.2.2 MoxDuo IR (Shire; China Aoxing; QRxPharma)
10.2.3 ALO-02 (Pfizer)
10.2.4 DETERx – COL-003 (Collegium Pharmaceuticals)
10.2.5 Acurox (Acura; Pfizer)
10.2.6 Morphine-6-Glucuronide (Paion)
10.2.7 Acuracet (Acura)
10.2.8 ARX-02 (AcelRx Pharmaceuticals)
10.2.9 Zohydro ER (Zogenix)
10.2.10 BEMA Buprenorphine (BioDelivery Sciences; Endo Pharmaceuticals)
10.3 Development Pipeline For Non-Narcotic Pain Relieving Drugs, 2014
10.3.1 Lofexidine Hydrochloride (US World Meds)
10.3.2 Synera (Nuvo Research)
10.3.3 Neosaxitoxin (Proteus SA; Boston Children Hospital)
10.3.4 OMS103 (Omeros)
10.3.5 Tetrodotoxin (CK Life Sciences; WEX Pharmaceuticals)
10.4 Development Pipeline For Neuropathic Pain Relieving Drugs, 2014
10.4.1 Perampanel (Eisai)
10.4.2 Serenbotase (Syntaxin, Ipsen, Allergan)
10.4.3 EMA401 (Spinifex Pharmaceuticals)
10.4.4 Ralfinamide (Newron)
10.4.5 NT-11624 (Neurotune)
10.4.6 AmiKet (Immune Pharmaceuticals)
10.4.7 Eladur (Durect; Impax Laboratories)
10.4.8 Clonidine Gel (Arcion Therapeutics; BioDelivery Sciences)
10.4.9 AVP-923 (Avanir Pharmaceuticals)
10.4.10 ARC-2022 (Arcion Therapeutics)
10.5 Development Pipeline For Anti-Migraine Pain Relieving Drugs, 2014
10.5.1 Zecuity (NuPathe; Teva)
10.5.2 Lasmiditan (CoLucid Pharmaceuticals)
10.5.3 NXN-188 (NeurAxon)
10.5.4 Levadex/Semprana (Allergan)
10.6 Development Pipeline For Anti-Arthritis Pain Relieving Drugs, 2014
10.6.1 Zavryl/Ibuprofen-PC (PLx Pharma)
10.6.2 Naproxcinod (NicOx)
10.6.3 Xeljanz (Pfizer)
10.6.4 Masitinib (AB Science)
10.6.5 Belimumab (GSK, Human Genome Sciences)
10.7 What Does the Future Hold for Pain Relieving Drugs Research and Development?
10.8 Solubility: A Hindrance To Drug Development
10.9 Monoclonal Antibodies (MAbs) – Potential Novel Pain Drugs Facing Challenges
10.10 New Opioids Providing Opportunities For Growth
10.11 The Potential Use Of Cannabinoids In Pain Relief
11. Qualitative Analysis for the Global Pain Relieving Drugs Market 2014-2024
11.1 Market Factors Influencing The Pain Relieving Drugs Market
11.2 SWOT Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.2.1 Strengths
11.2.1.1 Cost Effectiveness: A Major Driver for Growth
11.2.1.2 Promising Candidates In The R&D Pipeline
11.2.2 Weaknesses
11.2.2.1 Product Withdrawals And Slow Regulatory Approvals
11.2.2.2 Concerns Over Drug Side Effects
11.2.2.3 Education In Pain Management Is A Key Unmet Need
11.2.3 Opportunities
11.2.3.1 Reformulations Of Existing Drugs Will Drive Market Growth
11.2.3.2 Reforms In Narcotics Offer Growth Opportunities
11.2.3.3 Ageing Population – Growth Driver For Pain Relieving Drugs
11.2.3.4 The Economic Benefits Of Expansion Into Emerging Markets
11.2.3.5 OTC Switching May Help To Delay Generic Erosion
11.2.4 Threats
11.2.4.1 Patent Expiries Will Lead To Generic Competition
11.2.4.2 Regulatory And Pricing Scrutiny Could Suffocate Market Growth
11.2.4.3 Inadequate Reimbursement Levels: A Potential Restraint On Market Growth
11.3 STEP Analysis Of The Pain Relieving Drugs Market, 2014-2024
11.3.1 Social Factors Affecting The Pain Relieving Drugs Market
11.3.2 Technological Factors Affecting the Pain Relieving Drugs Market
11.3.3 Economic Factors Affecting The Pain Relieving Drugs Market
11.3.4 Political Factors Affecting The Pain Relieving Drugs Market
12. Expert Opinions
12.1 Interview With Dr Stephen K Doberstein, Senior Vice President And Chief Scientific Officer, Nektar Therapeutics
12.1.1 Pain Relieving Drugs: Current Trends In The Market
12.1.2 Nektar’s NKTR-181 Product And Its Mechanism To Mitigate Against Opioid Abuse
12.1.3 Key Developments In Pain Management And The Steps Being Taken To Reduce Addiction To Pain Drugs
12.1.4 Nektar’s Development Programme And Issues Around Penetration Of The Blood-Brain Barrier
12.1.5 Future Expansion Plans
12.1.6 On The Unmet Need For Abuse-Resistant And Highly Efficacious Pain Relieving Drugs
12.1.7 On The Developments Expected To Enter The Market In The Coming Years And The Need To Re-invent Known Classes Of Analgesic Molecules
12.2 Interview With Dr Tom McCarthy, Chief Executive Officer, Spinifex Pharmaceuticals
12.2.1 The Quest For Alternative Pain Relief Therapies
12.2.2 The Future Potential Of Combination Therapies In Pain Relief
12.2.3 On Developing, Validating and Demonstrating The Clinical Potential Of Novel Mechanisms For Tackling Pain
12.2.4 On The Market Potential Of Spinifex’s EMA401 Product
12.2.5 On Expansion Plans For EMA401 And Pain Relief As A Whole
12.2.6 The Drug Development And Commercialisation Challenges Facing The Pain Relieving Drugs Market
12.2.7 Future Outlook On The Market And The Potential For Novel Analgesics
13. Conclusions
13.1 Market Overview
13.2 The Likely Impacts Of Patent And Exclusivity Expiries On Pain Relieving Drugs
13.3 Major Growth Drivers For Pain Relieving Drugs
13.4 Under-Served Needs In Neuropathic Pain Leaves Room For Growth
13.5 The Narcotic Pain Relieving Drugs Market: Its Driving And Restraining Factors
13.6 Botox Approval Expected To Boost Anti-Migraine Submarket
13.7 The Rise Of Biological Anti-Arthritic Pain Drugs
13.8 Emerging Markets Set To Drive Steer Market Forward
13.9 What Does The Future Hold For Pain Relieving Drugs?
【レポート販売概要】
■ タイトル：世界の鎮痛剤（痛み止め）市場予測：麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬■ 英文：PAIN RELIEVING DRUGS MARKET FORECAST 2014-2024
Future Prospects for Leading Companies
■ 発行日：2014年9月
■ 調査会社：visiongain
■ 商品コード：VISG409041
■ 調査対象地域：グローバル
- プロテオミクスの世界市場分析：製品別（機器、試薬、サービス）、技術別（マイクロアレイ、X線結晶学、分光法、クロマトグラフィー、タンパク質分画システム、電気泳動、表面プラズマ共鳴システム）、用途別（創薬、臨床診断）、セグメント予測、2014-2025The global proteomics market is expected to reach over USD 24.8 billion by 2024 according to a new report by Grand View Research, Inc. The introduction of technology-enabled proteomics products is one of the high-impact rendering drivers for the proteomics market growth. These products find extensive applications in drug discovery, diagnostic services, and many other research areas. The increasing …
- Elvitegravir (HIV)：市場予測と分析（～2022）Elvitegravir (HIV) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Elvitegravir (HIV) - Forecast and Market Analysis to 2022”. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS …
- Nintedanib (Non-Small Cell Lung Cancer)：市場予測と分析（～2022）Nintedanib (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment l …
- Strike Energy Limited社の石油・ガス開発・生産動向及びコスト分析（2013年）Strike Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis - 2013 Summary Strike Energy Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- 燃料電池技術の分析：Analyzing Fuel Cell TechnologyThe race for developing a long term solution to increasing usage of fossil fuels in the automotive sector and the rising effect of greenhouse gases has a new participant ? Fuel Cell Technology. The advent of Fuel Cells though yet to achieve mass commercial successes has presented new clean opportunities for meeting energy requirements. The rising fuel prices globally and the increasing environment …
- 歩行支援デバイスの世界市場：介助ベルト、リフト・ベスト、杖、松葉杖、歩行器、車椅子、電動スクーターThe global walking assist device market is expected to reach USD 6.57 Billion by 2020, at a CAGR of 3.9% from 2015 to 2020. This report on the Global Market is analysed and segmented on the basis of product, and region. It analyzes the competitive developments, such as alliance, joint venture, and merger & acquisition of the global market. This market is also analyzed with an explicit focus on the …
- 無人水上艦（USV）の世界市場2017-2021About Unmanned Surface Vehicles (USVs) USVs are also known as ASVs. They are autonomous or semi-autonomous or can be operated with a remote controlling device. These vehicles are pre-programmed to perform certain defined tasks. Vendors in the marine system industry that have traditionally been dealing with unmanned underwater vehicles and unmanned aerial vehicles are expanding their scope to provi …
- A.P. Moller – Maersk A/S：石油・ガスの開発・生産動向及びコスト分析- Q1, 2013A.P. Moller - Maersk A/S Oil & Gas Exploration and Production Operations and Cost Analysis - Q1, 2013 Summary A.P. Moller - Maersk A/S Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential …
- エチルターシャリーブチルエーテル(ETBE)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world ethyl tertiary butyl ether market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together gi …
- GF（ガラス繊維）及びGFRP（ガラス繊維強化プラスチック）複合材の世界市場2016-2020About Composite Materials Composite materials are made of two or more materials with distinct physical and chemical properties, which when combined form a material that has characteristic properties different from the individual materials. GFRP composites are fiber-reinforced polymers that are made of plastic and reinforced with glass fibers (GFs) in a continuous stranded manner. The plastic used …
- 世界のマイクログリッド市場予測＆分析To provide tailored, efficient, and reliable energy services to the end users, microgrid employs and integrates a wide range of distributed energy technologies such as generation, storage and advanced controls, metering and communications into a controlled system that manages energy generation, transmission, distribution, and usage on a small scale as compared to the conventional macrogrid. The re …
- 個人用保護具（PPE）の世界市場分析：製品別（頭部、目と顔の保護、聴覚保護、保護服、呼吸保護、保護フットウェア、秋の保護、手の保護）、エンドユーザー別（建設、製造石油・ガス、化学薬品、食品、医薬品、輸送）、セグメント予測The global Personal Protective Equipment market is expected to reach USD 62.45 billion by 2022, according to a new study by Grand View Research, Inc. Increasing awareness towards employee health and safety coupled with rising industrial fatalities in emerging economies due to lack of protective gear is expected to drive market growth over the forecast period. Technological innovation, along with c …
- NANDフラッシュメモリの世界市場2016-2020About NAND Flash Memory NAND flash memory is a non-volatile storage technology that enables rapid read and write operations in memory cards. The memory cells in NAND flash memory chips are connected in a series that resembles a NAND gate. The series connection consumes less space than a parallel connection, reducing the cost of NAND flash chips. This makes the cost of NAND flash cards reasonable; …
- 医療廃棄物管理の世界市場2015-2022According to Stratistics MRC, the Global Medical Waste Management Market is valued at $10.78 billion in 2015 and is expected to grow at a CAGR of 5.9% to reach $16.2 billion by 2022. Huge quantity of waste generated by healthcare is one of the key factors driving the market growth. Rapidly growing healthcare industry will provide lucrative market opportunities for the service providers in the mark …
- ラボラトリーオートメーションシステムの世界市場2019-2023About this market Vendors have started offering software as an additional service with their laboratory automation systems, to maintain customer loyalty and ensure quality results. These software services are equipped with an intuitive and flexible user interface, which enables the analysis of data sample. These software services resemble the manual plating procedure. Apart from being compliant wi …
